A Phase I, Single-blind, Randomized Study of the Safety and Efficacy of Cellularized Integra® Using Autologous Burn-derived Stem Cells
A Phase I, Single-blind, Randomized Study of the Safety and Efficacy of Cellularized Integra® Using Autologous Burn-derived Stem Cells
Not yet recruiting · NCT05344521 · Registry updated 2023-12-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase I, Single-blind, Randomized Study of the Safety and Efficacy of Cellularized Integra® Using Autologous Burn-derived Stem Cells | Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, burn, injury, severe cutaneous adverse reaction | Not yet recruiting | Phase 1 | 2023-12-15 | NCT05344521 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AFP Innovation Fund | 6 |
| Hamilton Health Sciences Corporation | 60 |
| Ontario Institute for Regenerative Medicine | 3 |
| Stem Cell Network | 8 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hamilton General Hospital | Hamilton | Canada | 38 |